These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33219738)

  • 1. Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model.
    Buja A; Rivera M; De Polo A; Brino ED; Marchetti M; Scioni M; Pasello G; Bortolami A; Rebba V; Schiavon M; Calabrese F; Mandoliti G; Baldo V; Conte P
    Thorac Cancer; 2021 Jan; 12(1):13-20. PubMed ID: 33219738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated Direct Costs of Renal Cancer by Stage of Disease at Diagnosis and Phase of Its Management: A Whole-Disease Model.
    Buja A; De Luca G; Gatti M; Bonaldi F; Gardi M; Bortolami A; Sepulcri M; Bimbatti D; Baldo V; Scioni M; Maruzzo M; Basso U; Zagonel V;
    Clin Genitourin Cancer; 2023 Aug; 21(4):e252-e260. PubMed ID: 36906433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalization costs of lung cancer diagnosis in Turkey: Is there a difference between histological types and stages?
    Türk M; Yıldırım F; Yurdakul AS; Öztürk C
    Tuberk Toraks; 2016 Dec; 64(4):263-268. PubMed ID: 28393715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
    Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
    Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
    Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
    Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.
    Pompen M; Gok M; Novák A; van Wuijtswinkel R; Biesma B; Schramel F; Stigt J; Smit H; Postmus P
    Lung Cancer; 2009 Apr; 64(1):110-6. PubMed ID: 18805601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.
    Zeng X; Karnon J; Wang S; Wu B; Wan X; Peng L
    PLoS One; 2012; 7(10):e48323. PubMed ID: 23118985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lobectomy for early-stage lung carcinoma: a cost analysis of full thoracoscopy versus posterolateral thoracotomy.
    Ramos R; Masuet C; Gossot D
    Surg Endosc; 2012 Feb; 26(2):431-7. PubMed ID: 21898011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing costs of metastatic non small cell lung cancer in the Netherlands.
    Keusters WR; de Weger VA; Hövels A; Schellens JHM; Frederix GWJ
    Lung Cancer; 2017 Dec; 114():56-61. PubMed ID: 29173766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of non-small cell lung cancer in the Netherlands.
    van der Linden N; Bongers ML; Coupé VM; Smit EF; Groen HJ; Welling A; Schramel FM; Uyl-de Groot CA
    Lung Cancer; 2016 Jan; 91():79-88. PubMed ID: 26589654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel.
    Isla D; González-Rojas N; Nieves D; Brosa M; Finnern HW
    Clin Transl Oncol; 2011 Jul; 13(7):460-71. PubMed ID: 21775273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
    Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
    Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.
    Migliorino MR; Santo A; Romano G; Cortinovis D; Galetta D; Alabiso O; Cartenì G; Vari S; Fasola G; Pazzola A; Giuffrida D; Zaniboni A; Caprioli A; Longo F; Acciai V; de Marinis F
    J Cancer Res Clin Oncol; 2017 May; 143(5):783-791. PubMed ID: 28215027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
    Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
    JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-of-illness study for non-small-cell lung cancer using real-world data.
    Seung SJ; Hurry M; Hassan S; Walton RN; Evans WK
    Curr Oncol; 2019 Apr; 26(2):102-107. PubMed ID: 31043811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico.
    Añorve Bailon D; Picó-Guzmán J; Cifuentes S; Trejo R; Rodríguez Cid J; Juarez-Vignon Whaley JJ; Heredia Zepeda AA; Gerson R; Camacho-Limas CP; Martínez-Herrera JF; Molina DB; Camarín Sánchez E; Shveid Gerson D
    Pharmacoecon Open; 2024 Nov; 8(6):869-885. PubMed ID: 39107537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell lung cancer in Spain.
    González García J; Gutiérrez Nicolás F; Nazco Casariego GJ; Valcárcel Nazco C; Batista López JN; Oramas Rodríguez J
    Farm Hosp; 2017 Jan; 41(n01):3-13. PubMed ID: 28045649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.